VTechWorks staff will be away for the winter holidays starting Tuesday, December 24, 2024, through Wednesday, January 1, 2025, and will not be replying to requests during this time. Thank you for your patience, and happy holidays!

Scholarly Works, School of Neuroscience

Permanent URI for this collection

https://hdl.handle.net/10919/84996
Research articles, presentations, and other scholarship

Browse

Browsing Scholarly Works, School of Neuroscience by Subject "0304 Medicinal and Biomolecular Chemistry"

Now showing 1 - 1 of 1
  • Thumbnail Image
    A glutamate concentration-biased allosteric modulator potentiates NMDA-induced ion influx in neurons
    Costa, Blaise M.; Kwapisz, Lina Cortes; Mehrkens, Brittney; Bledsoe, Douglas N.; Vacca, Bryanna N.; Johnston, Tullia V.; Razzaq, Rehan; Manickam, Dhanasekaran; Klein, Bradley G. (Wiley, 2021-10-01)
    Precisely controlled synaptic glutamate concentration is essential for the normal function of the N-methyl D-aspartate (NMDA) receptors. Atypical fluctuations in synaptic glutamate homeostasis lead to aberrant NMDA receptor activity that results in the pathogenesis of neurological and psychiatric disorders. Therefore, glutamate concentration-dependent NMDA receptor modulators would be clinically useful agents with fewer on-target adverse effects. In the present study, we have characterized a novel compound (CNS4) that potentiates NMDA receptor currents based on glutamate concentration. This compound alters glutamate potency and exhibits no voltage-dependent effect. Patch-clamp electrophysiology recordings confirmed agonist concentration-dependent changes in maximum inducible currents. Dynamic Ca2+ and Na+ imaging assays using rat brain cortical, striatal and cerebellar neurons revealed CNS4 potentiated ion influx through native NMDA receptor activity. Overall, CNS4 is novel in chemical structure, mechanism of action and agonist concentration-biased allosteric modulatory effect. This compound or its future analogs will serve as useful candidates to develop drug-like compounds for the treatment of treatment-resistant schizophrenia and major depression disorders associated with hypoglutamatergic neurotransmission.